Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report-Reference-Cited by-同舟云学术

Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report

Published:2022-02-21 Issue:4 Volume:33 Page:406-412
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Deng Youjun,Yang Chenglin,Liu Wenyi,Cai Songhua,Guo Xiaotong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference10 articles.

1. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.;Vyse;Signal Transduct Target Ther,2019

2. EGFR mutations in Asian patients with advanced lung adenocarcinoma.;Liam;J Thorac Oncol,2014

3. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.;Yasuda;Lancet Oncol,2012

4. Clinical outcomes of EGFR Exon 20 insertion mutations in advanced non-small cell Lung cancer in Korea.;Byeon;Cancer Res Treat,2019

5. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib.;Naidoo;Cancer,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI;Frontiers in Pharmacology;2024-02-19

2. Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series;Oncology Letters;2022-09-22

3. Aumolertinib/bevacizumab/pemetrexed;Reactions Weekly;2022-05